Much of the research about depression in children and adolescents focuses on how to treat the illness during the acute phase. This review from the Cochrane Depression, Anxiety and Neurosis Review Group is more concerned with the ways in which interventions can be used to prevent relapse or recurrence of depressive disorders. The review looks specifically at two [read the full story…]
Research has shown that antidepressant use can lead to a non-significant increase in the risk of suicidal thoughts and behaviour in people aged under 25 (Stone et al, BMJ 2009). This subject rightly received a large amount of media coverage a few years ago and it remains an area where new studies can add to [read the full story…]
There are many different antidepressants to choose from when treating acute depression, so it’s always helpful to see a systematic review that looks at the efficacy, acceptability and tolerability of the different drugs. This new Cochrane review compares duloxetine hydrochloride (one of the newer drugs) with other antidepressants and finds little high quality evidence upon [read the full story…]
Orofacial pain is a relatively common and is categorized into musculoskeletal; neuropathic; vascular; neurovascular; idiopathic; pain caused by local, distant, or systemic pathology; and psychogenic. Diagnosis can be challenging when psychosocial factors are present and while antidepressants have been used as a treatment there remains some controversy. The aim of this review was to assess [read the full story…]
There has been a lot of discussion over recent years about the ways in which genetic testing may help make the treatment of depression become more targeted and effective. The theory is that genetic markers may help predict how different people are likely to respond to different drugs. This is clearly something that would interest [read the full story…]
The Scottish Government have published their annual summary of prescribing statistics for mental health drugs. The report shows increases in the prescribing rates for all groups of drugs over the last 12 months. The prescribing costs of some groups of drugs have also risen (ADHD, dementia, depression) although other groups have seen a decline (insomnia [read the full story…]
I really enjoyed the discussion in the Guardian over the weekend about poor quality trials and pharmaceutical industry techniques that overhype their drugs in an attempt to shift units. Ben Goldacre’s new Bad Pharma book is well worth a read. New reviews about antidepressants come thick and fast and it’s often hard to know what [read the full story…]
One of the criticisms that health professionals sometimes make of evidence-based research is that individual studies or reviews do not apply to the specific patient they are caring for. Of course, each patient is unique with their own values and preferences, as well as their own particular clinical characteristics, genetic make-up, biological markers and sociodemographic [read the full story…]
Polypharmacy is the simultaneous use of two or more drugs to treat a single health condition. Polypharmacy is often used in the treatment of schizophrenia where people are regularly prescribed two or more antipsychotics, as well as antidepressants and/or benzodiazepines, although there is little evidence to prove that these combinations are more effective than monotherapy. [read the full story…]
Following the media coverage of the NHS statistics published last week that reported a large rise in antidepressant prescribing, Martin Brunet (a GP from Surrey and author of the excellent Binscombe Doctor Blog) has written an opinion piece that explores the positive and negative aspects of this complex story: “Are GPs prescribing antidepressants too readily?” [read the full story…]
